Pharmacodynamic Study

OTHER7 trials

Sponsors

National Cancer Institute (NCI), M.D. Anderson Cancer Center, Mayo Clinic, City of Hope Medical Center, University of Arizona

Conditions

Advanced Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8CDKN2A-p16 PositiveEsophageal Adenocarcinoma

Phase 1

IACS-010759 in Advanced Cancers

CompletedNCT03291938

M.D. Anderson Cancer CenterAdvanced Malignant Solid Neoplasm, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8 +22

Start: 2017-11-13End: 2020-11-23Updated: 2020-11-24

Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer

CompletedNCT03290937

M.D. Anderson Cancer CenterMetastatic Colorectal Carcinoma, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8 +2

Start: 2017-12-27End: 2025-12-30Updated: 2026-01-06

Phase 2

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

Active, not recruitingNCT02152995

National Cancer Institute (NCI)Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma +9

Start: 2014-08-14End: 2027-02-05Updated: 2026-04-03

Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

TerminatedNCT03506373

Mayo ClinicRecurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia, Waldenstrom Macroglobulinemia

Start: 2018-08-14End: 2026-02-03Updated: 2026-03-05

Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer

WithdrawnNCT03592407

City of Hope Medical CenterEsophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma

Start: 2018-07-01End: 2020-04-30Updated: 2022-03-08

Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer

TerminatedNCT03601507

University of ArizonaCDKN2A-p16 Positive, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 +3

Start: 2019-03-11End: 2022-05-24Updated: 2024-04-17

Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

Active, not recruitingNCT03872427

National Cancer Institute (NCI)Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor +1

Start: 2019-12-14End: 2026-04-16Updated: 2025-11-14

Related Papers

[<sup>18</sup>F]TFB PET/CT misses intense [<sup>124</sup>I]iodine-avid metastases after redifferentiation therapy in metastatic thyroid cancer.

2024-10-08

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.

2023-01-19280 citations

Phase 2 of trametinib plus radioiodine in <i>RAS-</i>mutant and wild-type, radioiodine-refractory thyroid cancer (ETCTN9446).

Journal of Clinical Oncology2022-06-019 citations

Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors.

Journal of Clinical Oncology2019-05-2066 citations

Ibrutinib-Resistant Mantle Cell Lymphoma Undergoes Metabolic Reprogramming Towards Oxphos

Blood2018-11-29

Abstract 1655: Discovery and development of IACS-010759, a novel inhibitor of Complex I currently in phase I studies to exploit oxidative phosphorylation dependency in acute myeloid leukemia and solid tumors

Cancer Research2018-07-015 citations